Trader consensus on Polymarket heavily favors no Encore Medical IPO before June 2026 at 81% implied probability, driven by repeated misses on anticipated pricing dates—including April 22, early May targets around May 6–10, and previews hinting at mid-May—without SEC declaration of effectiveness for its S-1 registration statement (originally filed September 2025, amended March 2026) or roadshow announcements. The Eagan, MN-based medtech developer's proposed $15 million offering of 3 million shares at $5.00 implies a fully diluted market cap near $50 million, clustering conditional odds around 45M–55M buckets at 8–14% each amid clinical-stage risks for its EU-approved PFO closure device. Choppy micro-cap IPO sentiment and lack of fresh catalysts like trial data sustain delay pricing, with resolution looming May 31.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日2026年6月以前にIPOしない 81%
5,500万ドル以上 7.8%
4,500万〜5,000万ドル 7%
4,500万ドル未満 2.8%
$24,003 Vol.
$24,003 Vol.
2026/04/22
4,500万ドル未満
3%
4,500万〜5,000万ドル
7%
50M–55M
8%
5,500万ドル以上
8%
2026年6月以前にIPOしない
81%
2026年6月以前にIPOしない 81%
5,500万ドル以上 7.8%
4,500万〜5,000万ドル 7%
4,500万ドル未満 2.8%
$24,003 Vol.
$24,003 Vol.
2026/04/22
4,500万ドル未満
$7,323 Vol.
3%
4,500万〜5,000万ドル
$2,625 Vol.
7%
50M–55M
$1,759 Vol.
8%
5,500万ドル以上
$3,121 Vol.
8%
2026年6月以前にIPOしない
$9,175 Vol.
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket heavily favors no Encore Medical IPO before June 2026 at 81% implied probability, driven by repeated misses on anticipated pricing dates—including April 22, early May targets around May 6–10, and previews hinting at mid-May—without SEC declaration of effectiveness for its S-1 registration statement (originally filed September 2025, amended March 2026) or roadshow announcements. The Eagan, MN-based medtech developer's proposed $15 million offering of 3 million shares at $5.00 implies a fully diluted market cap near $50 million, clustering conditional odds around 45M–55M buckets at 8–14% each amid clinical-stage risks for its EU-approved PFO closure device. Choppy micro-cap IPO sentiment and lack of fresh catalysts like trial data sustain delay pricing, with resolution looming May 31.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Apr 3, 2026, 7:59 PM ET
音量
$24,003終了日
2026/04/22マーケット開始日
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket heavily favors no Encore Medical IPO before June 2026 at 81% implied probability, driven by repeated misses on anticipated pricing dates—including April 22, early May targets around May 6–10, and previews hinting at mid-May—without SEC declaration of effectiveness for its S-1 registration statement (originally filed September 2025, amended March 2026) or roadshow announcements. The Eagan, MN-based medtech developer's proposed $15 million offering of 3 million shares at $5.00 implies a fully diluted market cap near $50 million, clustering conditional odds around 45M–55M buckets at 8–14% each amid clinical-stage risks for its EU-approved PFO closure device. Choppy micro-cap IPO sentiment and lack of fresh catalysts like trial data sustain delay pricing, with resolution looming May 31.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$24,003終了日
2026/04/22マーケット開始日
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader consensus on Polymarket heavily favors no Encore Medical IPO before June 2026 at 81% implied probability, driven by repeated misses on anticipated pricing dates—including April 22, early May targets around May 6–10, and previews hinting at mid-May—without SEC declaration of effectiveness for its S-1 registration statement (originally filed September 2025, amended March 2026) or roadshow announcements. The Eagan, MN-based medtech developer's proposed $15 million offering of 3 million shares at $5.00 implies a fully diluted market cap near $50 million, clustering conditional odds around 45M–55M buckets at 8–14% each amid clinical-stage risks for its EU-approved PFO closure device. Choppy micro-cap IPO sentiment and lack of fresh catalysts like trial data sustain delay pricing, with resolution looming May 31.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問